CTSK
Cathepsin K
As of the edition of 20 October 2026, CTSK (cathepsin K, UniProt P43235) has 5 drugs tested at it and 5 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43235
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 71
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Cancer; Skin and connective tissue; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 29
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 4 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Odanacatib | Stopped | Phase 3 | none listed |
| Balicatib | Went quiet | Phase 2 | none listed |
| MIV-711 | Went quiet | Phase 2 | none listed |
| ONO-5334 | Went quiet | Phase 2 | none listed |
| Relacatib | Went quiet | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Novartis | Route A |
| GSK | Route A |
The other 2 companies at CTSK
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at CTSK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.